Nepsis Inc. Purchases 1,994,555 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Nepsis Inc. lifted its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 2,072.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,090,812 shares of the company's stock after buying an additional 1,994,555 shares during the quarter. Health Catalyst comprises about 2.3% of Nepsis Inc.'s portfolio, making the stock its 22nd largest holding. Nepsis Inc. owned approximately 2.98% of Health Catalyst worth $9,471,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in Health Catalyst in the 4th quarter valued at $735,000. Wells Fargo & Company MN boosted its position in shares of Health Catalyst by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,355 shares of the company's stock valued at $278,000 after acquiring an additional 8,451 shares during the period. Impax Asset Management Group plc grew its stake in shares of Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after acquiring an additional 195,525 shares in the last quarter. Two Sigma Investments LP bought a new position in Health Catalyst during the fourth quarter worth about $496,000. Finally, Raymond James Financial Inc. bought a new position in Health Catalyst during the fourth quarter worth about $2,044,000. Institutional investors own 85.00% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on HCAT. Royal Bank of Canada lowered their price objective on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 27th. Canaccord Genuity Group decreased their price target on Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. KeyCorp cut their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Evercore ISI lowered shares of Health Catalyst from an "outperform" rating to an "inline" rating in a report on Wednesday, April 9th. Finally, Stifel Nicolaus upped their price target on shares of Health Catalyst from $5.00 to $5.50 and gave the stock a "hold" rating in a report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Health Catalyst Price Performance

HCAT stock traded up $0.02 during trading on Thursday, reaching $3.98. 656,504 shares of the company were exchanged, compared to its average volume of 604,720. The company has a market capitalization of $277.01 million, a price-to-earnings ratio of -2.95 and a beta of 1.53. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a 50-day moving average of $3.94 and a two-hundred day moving average of $5.30. Health Catalyst, Inc. has a twelve month low of $3.49 and a twelve month high of $9.24.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.